Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates

Jia A. Mei1, William Johnson2, Bailey Kinn1, Emily Laskey1, Lydia Nolin1, Pratham Bhamare1, Charlotte Stalker1, Paul M. Dunman1, and Rachel A. F. Wozniak2

1 Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
2 Department of Ophthalmology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

Correspondence: Rachel A. F. Wozniak, Department of Ophthalmology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Box 659, Rochester, NY 14642, USA. e-mail: rachel_wozniak@urmc.rochester.edu

Received: February 8, 2022
Accepted: May 4, 2022
Published: May 25, 2022

Keywords: keratitis; antibiotic; drug development; Pseudomonas

Citation: Mei JA, Johnson W, Kinn B, Laskey E, Nolin L, Bhamare P, Stalker C, Dunman PM, Wozniak RAF. Antimicrobial activity of a triple antibiotic combination toward ocular pseudomonas aeruginosa clinical isolates. Transl Vis Sci Technol. 2022;11(5):26, https://doi.org/10.1167/tvst.11.5.26

Purpose: Pseudomonas aeruginosa is a leading cause of corneal infections. Recently, we discovered an antimicrobial drug combination, polymyxin B/trimethoprim (PT) + rifampin, that displayed impressive efficacy toward P. aeruginosa in both in vitro and in vivo studies. As such, this combination was further evaluated as a potential keratitis therapeutic through testing the combination’s efficacy against a diverse set of P. aeruginosa clinical isolates.

Methods: Minimum inhibitory concentrations (MICs) of moxifloxacin, levofloxacin, erythromycin, tobramycin, PT, polymyxin B (alone), trimethoprim (alone), and rifampin were determined for 154 ocular clinical P. aeruginosa isolates, 90% of which were derived from corneal scrapings. Additionally, the efficacy of PT + rifampin was evaluated utilizing fractional inhibitory concentration (FIC) testing.

Results: While 100% of isolates were resistant to erythromycin (average MIC 224 ± 110 μg·mL⁻¹) and trimethoprim (alone) (206 ± 67.3 μg·mL⁻¹), antibiotic resistance was generally found to be low: moxifloxacin (2% of isolates resistant; average MIC 1.08 ± 1.61 μg·mL⁻¹), levofloxacin (3.9%; 1.02 ± 2.96 μg·mL⁻¹), tobramycin (1%; 0.319 ± 1.31 μg·mL⁻¹), polymyxin B (0%; 0.539 ± 0.206 μg·mL⁻¹), PT (0%; 0.416 ± 0.135 μg·mL⁻¹), and rifampin (0%; 23.4 ± 6.86 μg·mL⁻¹). Additionally, FIC testing revealed that PT + rifampin eradicated 100% of isolates demonstrating additive or synergistic activity in 95% of isolates (average FIC index 0.701 ± 0.132).

Conclusions: The drug combination of PT + rifampin was effective against a large panel of clinically relevant P. aeruginosa strains and, as such, may represent a promising therapeutic for P. aeruginosa keratitis.

Translational Relevance: This work furthers the preclinical development of a novel antibiotic combination for the treatment of corneal infections (bacterial keratitis).

Introduction

Bacterial keratitis (corneal infection) is a serious disease requiring urgent topical antimicrobial treatment to mitigate ocular tissue damage and preserve vision. While a wide variety of micro-organisms have been implicated in bacterial keratitis, Pseudomonas aeruginosa stands out as the leading Gram-negative pathogen implicated in this disease, particularly in contact lens wearers.1–3 In fact, some studies have indicated that among all organisms responsible for contact lens–associated keratitis, the prevalence of P. aeruginosa can be as high as 70%.4–6 With a current estimated 38.5 million contact lens wearers in the United States7 and the rising popularity of multifocal, toric, and novelty contact lenses, P. aeruginosa keratitis has become a major health care and ophthalmic concern.

Currently, topical ophthalmic fluoroquinolones are widely used in the treatment of P. aeruginosa bacterial keratitis given their broad-spectrum activity, excellent tissue penetration, and patient tolerability. Fortunately, in the United States, circulating...
antibiotic resistance among ocular *P. aeruginosa* isolates toward fluoroquinolones as well as other ophthalmic antibiotics has remained low. However, reports are now emerging describing significant *P. aeruginosa* resistance globally. For example, *P. aeruginosa* resistance to moxifloxacin, a commonly utilized fourth-generation fluoroquinolone as well as the aminoglycoside gentamicin, has been reported upward of 50% in large patient series based in India. Unfortunately, the clinical consequences of resistant infections are significant and include increased disease severity and worse visual outcomes. However, despite this worrisome trend of emerging antibiotic resistance, there is a paucity of commercial alternatives to fluoroquinolones in the treatment of keratitis.

We recently described the synergistic antimicrobial activity of a novel drug combination, polymyxin B/trimethoprim (PT) + rifampin toward *P. aeruginosa* and *Staphylococcus aureus*, another leading cause of keratitis, in both in vitro and in vivo studies. While PT alone is commonly used for the treatment of mild bacterial conjunctivitis, its use in more serious corneal infections is limited due to weak antimicrobial potency and inadequate tissue penetration compared to fluoroquinolones. However, we have demonstrated that the combination of PT + rifampin overcomes these liabilities and displays antimicrobial efficacy in a murine model of bacterial keratitis that equals or exceeds that of fourth-generation fluoroquinolones. Importantly, PT + rifampin exhibits in vivo efficacy toward fluoroquinolone-resistant *S. aureus* and *P. aeruginosa* strains, suggesting that it may be an effective treatment option for infections that otherwise might fail currently available options.

To further investigate the incidence of antibiotic resistance and expand understanding of the potential therapeutic value of PT + rifampin for bacterial keratitis, we performed antimicrobial activity assays on a contemporary collection of 154 *P. aeruginosa* clinical ocular isolates. The entire strain set was first evaluated for antibiotic resistance to a panel of antibiotics that are commonly used for ocular treatment, including erythromycin, PT, levofloxacin, moxifloxacin, and tobramycin. Second, we evaluated the antimicrobial efficacy of PT + rifampin as well as rifampin (alone), trimethoprim (alone), and polymyxin B (alone) toward the entire isolate collection. Third, we evaluated whether the antimicrobial performance of PT + rifampin is a consequence of the combination’s synergistic effects. Collectively, our results demonstrate that with the exception of erythromycin and trimethoprim, resistance levels remain low among US ocular *P. aeruginosa* isolates. Additionally, we establish that the combination of PT + rifampin displays potent antimicrobial activity with 100% of the isolate collection susceptible to the combination, including strains resistant to fluoroquinolones. Further, we show that the antimicrobial effectiveness of PT + rifampin is associated with the combination’s synergistic effects. Thus, PT + rifampin may represent a potential novel therapeutic to treat this blinding disease.

### Materials and Methods

#### Bacterial Strains and Growth Conditions

A total of 154 *P. aeruginosa* clinical ocular isolates were commercially obtained from International Health Management Associates (IHMA) (Schaumburg, IL, USA). Individual isolates were grown overnight and subcultured in fresh Mueller–Hinton (MH) media shaking with aeration at 37°C to early exponential phase. A range of OD<sub>600</sub> = 0.2 to 0.4 was found to correspond to approximately 10<sup>8</sup> colony-forming units (CFU)/mL, and subcultures were then diluted 1:100 in fresh media for subsequent minimum inhibitory concentration (MIC) and fractional inhibitory concentration (FIC) testing. The pan-sensitive laboratory strain PAO1 was used as a control for this study.

#### MIC

Each clinical isolate was tested for susceptibility to a panel of eight clinically relevant antibiotics, including erythromycin, PT, rifampin, moxifloxacin, levofloxacin, trimethoprim, tobramycin, and polymyxin B, using the standard MIC testing guidelines. Individual wells of a 96-well microtiter plate were prepared by adding 88 μL of fresh MH broth, 2 μL of increasing concentrations of each antibiotic, and 10 μL of the appropriate bacterial culture to achieve a final concentration of 10<sup>4</sup> CFU/well and incubated for 16 hours at 37°C. The MIC value for each antibiotic was determined as the lowest concentration of antibiotic that inhibited bacterial growth as visualized by the naked eye. Resistance was characterized as having an MIC value of ≥4 μg/mL for levofloxacin, ≥16 μg/mL for tobramycin, and ≥4 μg/mL for polymyxin B per the 2021 Clinical and Laboratory Standards Institute (CLSI). Resistance for the remaining antibiotics (PT, rifampin, and moxifloxacin) was characterized as having MIC values ≥4× the MIC value for a susceptible laboratory strain, PAO1. Erythromycin and trimethoprim were
used as controls due to the known insusceptibility of *P. aeruginosa* to these antibiotics.20

**FIC Testing of PT + Rifampin**

A standard checkerboard assay was done to determine the efficacy of the drug combination (PT plus rifampin) on the clinical strain set according to CLSI guidelines.19 In total, 10 μL of the indicated $10^6$ CFU/mL bacterial culture was added to 88 μL MH media and 2 μL of antibiotics in individual wells of a 96-well microtiter plate with each column containing twofold increasing concentrations of PT (0.0–2.5 μg/mL) and each row containing twofold increasing concentrations of rifampin (0.0–60 μg/mL). PT + rifampin drug combinations were prepared separately in 200 μL to minimize pipetting errors. The plates were then incubated for 16 hours at 37°C and visually inspected for growth. The fraction inhibitory concentration index (FICI) was calculated using the following formula: $\text{FICI} = (\text{MIC of PT in combination} / \text{MIC of PT alone}) + (\text{MIC of rifampin in combination} / \text{MIC of rifampin alone}).$ The averaged FICI from three biological replicates was defined as either synergistic ($\text{FICI} < 0.5$), additive ($0.5–1$), indifference ($1–4$), or antagonistic ($\text{FICI} > 4$).21

**Results**

**Strain Set Characteristics**

In total, 154 ocular *P. aeruginosa* isolates were obtained from IOMHA between 2016 and 2020. Table 1 provides the characteristics of the strain set. Forty-six percent ($n = 71$) of isolates were collected from male patients and 54% ($n = 83$) from female patients. Ages of patients at the time of isolate collection ranged from 1 to 104, with the majority of patients aged 40 to 59 (31%) and 60 to 79 years (27%). Ninety percent of the isolates were isolated from corneal scrapings, and 10% were broadly categorized as from eyes that could include corneal, conjunctival, intracameral, and/or intravitreal samples. The geographic representation included 139 (90%) of isolates from North America, 13 (8%) from Europe, 1 (1%) from Latin America, and 1 (1%) from Asia. Among isolates collected from the United States, 15 states were represented: Alabama ($n = 5$), California ($n = 46$), Colorado ($n = 3$), Florida ($n = 32$), Illinois ($n = 5$), Indiana ($n = 8$), Iowa ($n = 1$), Kentucky ($n = 4$), Michigan ($n = 3$), New Mexico ($n = 4$), New York ($n = 18$), North Carolina ($n = 1$), Texas ($n = 3$), Utah ($n = 5$), and Wisconsin ($n = 1$).

| Characteristic                  | n (%) |
|--------------------------------|-------|
| **Sex**                        |       |
| Male                           | 71 (46)|
| Female                         | 83 (54)|
| **Age, y**                     |       |
| 0–19                           | 10 (6) |
| 20–39                          | 29 (19)|
| 40–59                          | 47 (31)|
| 60–79                          | 41 (27)|
| 80–104                         | 27 (18)|
| **Source**                     |       |
| Cornea                         | 138 (90)|
| Eye                            | 16 (10)|
| **Geography**                  |       |
| North America                  | 139 (90)|
| Europe                         | 13 (8) |
| Latin America                  | 1 (1)  |
| Asia                           | 1 (1)  |
| **Year collected**             |       |
| 2016                           | 22 (14)|
| 2017                           | 18 (12)|
| 2019                           | 45 (29)|
| 2020                           | 69 (45)|

**Antibiotic Resistance Profiles of Isolates toward Commercially Available Ophthalmic Antibiotics**

MIC testing was performed on the entire strain set in triplicate to measure the effectiveness of five commonly used ophthalmic antibiotics: moxifloxacin, levofloxacin, erythromycin, tobramycin, and PT. Additionally, to further support the preclinical development of the novel drug combination PT + rifampin as a potential keratitis therapeutic, MIC testing was completed for the individual components: trimethoprim (alone), polymyxin B (alone), and rifampin. Resistance was characterized as having an MIC value above the 2021 CLSI break point when available or an MIC value $\geq 4 \times$ the MIC value for a susceptible laboratory strain, PAO1.

MIC testing revealed that overall resistance was very low among this set of clinical isolates, with only six strains (3.9%) resistant to one antibiotic and one strain that demonstrated multidrug resistance as defined by resistance to three or more classes of antibiotics (Table 2, Supplementary Table S1). More specifically, as expected, 100% of isolates were resistant to erythromycin (average MIC $224 \pm 110 \, \mu g\cdot mL^{-1}$) and trimethoprim ($206 \pm 67.3 \, \mu g\cdot mL^{-1}$) due to known
Table 2. Antibiotic Resistance among the 154-Member Clinical Strain Set

| Antibiotic          | Overall Resistance, n (%) | MIC, Mean ± SD, μg·mL⁻¹ |
|---------------------|---------------------------|-------------------------|
| Moxifloxacin        | 3 (1.95)                  | 1.08 ± 1.61             |
| Levofloxacin        | 6 (3.90)                  | 1.02 ± 2.96             |
| Tobramycin          | 1 (0.65)                  | 0.319 ± 1.31            |
| Erythromycin        | 154 (100)                 | 224 ± 110               |
| Polymyxin B/trimethoprim | 0 (0)            | 0.416 ± 0.135           |
| Polymyxin B         | 0 (0)                     | 0.539 ± 0.206           |
| Trimethoprim        | 154 (100)                 | 206 ± 67.3              |
| Rifampin            | 0 (0)                     | 23.4 ± 6.86             |
| Resistant to ≥1 antibiotic | 6 (3.90)      | —                       |
| Resistance to ≥3 antibiotics | 1 (0.65)  | —                       |

P. aeruginosa insusceptibility to these antibiotics. In contrast, resistance toward fluoroquinolones was low, with only three strains resistant to moxifloxacin (1.08 ± 1.61 μg·mL⁻¹) and six strains resistant to levofloxacin (1.02 ± 2.96 μg·mL⁻¹). Only one strain was found to be resistant to tobramycin (0.319 ± 1.31 μg·mL⁻¹), and 100% of isolates were sensitive to PT (0.416 ± 0.135 μg·mL⁻¹), polymyxin B (alone) (0.539 ± 0.206 μg·mL⁻¹), and rifampin (23.4 ± 6.86 μg·mL⁻¹).

Potent Antimicrobial Activity of PT + Rifampin

Previous studies have demonstrated that the combination of PT + rifampin is a synergistic, broad-spectrum antimicrobial. Moreover, PT + rifampin has also been shown to effectively eradicate both P. aeruginosa and S. aureus murine keratitis infections caused by antibiotic-resistant strains. Thus, in order to further investigate the therapeutic promise of PT + rifampin, we tested the antimicrobial susceptibility of the entire strain set to the combination.

The triple antibiotic combination, PT + rifampin, demonstrated synergistic or additive antimicrobial activity in 146 isolates (95%) with FICI values ranging from 0.446 to 1.005 (average 0.701 ± 0.132) (Table 3, Supplementary Table S2). Specifically, PT + rifampin displayed synergistic activity toward three isolates (average FICI 0.457 ± 0.012) and additive toward 143 isolates (FICI 0.690 ± 0.111), and the combination had a neutral effect toward the remaining eight isolates (FICI = 1 ± 0.002). In line with these findings, we found a corresponding reduction in the MICs for both PT and rifampin when the drugs were tested against the clinical strain set in combination versus alone. For example, on average, there was a twofold reduction in the MIC for PT when measured alone versus in combination with rifampin (0.416 ± 0.135 μg/mL vs. 0.180 ± 0.045 μg/mL) and a fourfold reduction in the MIC of rifampin when in combination with PT versus alone (23.4 ± 6.86 μg/mL vs. 5.41 ± 3.11 μg/mL) (Table 3). Importantly, PT + rifampin displayed this potent activity, even toward drug resistant isolates. For example, IHMA1564153, a multidrug-resistant strain with resistance to moxifloxacin, levofloxacin, and tobramycin, was found to be highly susceptible to PT + rifampin with a synergistic FICI value of 0.458 ± 0.072. Moreover, the efficacy of PT + rifampin was equivalent when comparing fluoroquinolone-resistant versus fluoroquinolone-sensitive isolates. The average FICI value of all six levofloxacin-resistant isolates (three of which were also resistant to moxifloxacin) was found to be 0.681 ± 0.18, compared to 0.702 ± 0.132 for all fluoroquinolone-sensitive strains.

Taken together, these data demonstrate the potent antimicrobial activity of the combination of PT + rifampin and its ability to effectively eradicate 100%
of this clinically relevant strain set. While overall resistance of *P. aeruginosa* keratitis isolates remains low, the PT + rifampin can successfully overcome existing antibiotic resistance with equal efficacy compared to antibiotic-sensitive strains, an important prerequisite for the development of any novel therapeutic agent.

**Discussion**

Antibiotic resistance is currently one of the most pressing concerns in modern medicine, resulting in significant clinical adverse outcomes due to treatment failures in addition to escalating health care costs.23–25 *P. aeruginosa*, one of the most common causes of ocular infections, has been designated by the Centers for Disease Control and Prevention as an ESRAPE pathogen, one of a group of six organisms of particular health care concern given their ability to “escape” traditional antimicrobial therapies as well as a “serious threat” in the recently published 2019 Antibiotic Resistant Threats in the United States.26 Fortunately, however, our current data indicate very low circulating antibiotic resistance among *P. aeruginosa* ocular isolates, a finding that is supported by other large-scale surveillance studies. For example, the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) study reported resistance rates of approximately 5% or lower to fluoroquinolones such as ofloxacin, ciprofloxacin, levofloxacin, and gatifloxacin in a set of nearly 700 clinical isolates collected from 2009 to 2018 in the United States.27

Despite the current reassuring low rates of antibiotic resistance among *P. aeruginosa* ocular isolates in the United States, reports from India describe emerging antibiotic resistance particularly toward fluoroquinolones, the mainstay of treatment of corneal infections. Given that resistance will undoubtedly rise, the development of novel antimicrobial therapeutics is essential to stay ahead of the curve. In response to this growing need, we have recently described a novel drug combination containing PT + rifampin that displays impressive antimicrobial activity toward the two most common causes of keratitis, *S. aureus* and *P. aeruginosa*.14,15 Importantly, the potent activity of PT + rifampin extended to an in vivo keratitis model, where it was shown to successfully eradicate *P. aeruginosa* and *S. aureus* corneal infections, even those caused by fluoroquinolone-resistant clinical isolates.14,15 Thus, to further advance our understanding of the therapeutic potential of PT + rifampin, we evaluated the combination’s activity toward a diverse panel of clinically relevant ocular isolates.

Our results indicate that the combination of PT + rifampin is effective toward contemporary circulating *P. aeruginosa* strains, including those that are resistant to one or more currently available antibiotics. Importantly, the combination of PT + rifampin appears to be synergistic or additive toward 95% of these isolates, as reflected in the decreased concentrations of PT and rifampin required for efficacy when in combination compared to each agent individually.

Given that current standard of care necessitates intensive, frequent dosing of topical antibiotics in cases of severe keratitis, the potency of PT + rifampin may allow for reduced dosing schedules for patients and potentially decreased toxicity to the ocular surface. The effectiveness of this combination may be due, in part, to its multiple mechanisms of action. While polymyxin B acts as a detergent to disrupt bacterial cell membranes, trimethoprim inhibits bacterial DNA synthesis through the inhibition of dihydrofolate reductase, and rifampin inhibits DNA transcription through binding to bacterial RNA polymerase.28–30

In summary, in an era of rising antibiotic resistance, the need for novel therapeutics is critical. This is particularly true for the treatment of keratitis, in which immediate empiric therapy that can successfully contend with circulating antibiotic resistance is necessary to prevent permanent ocular tissue damage. We have demonstrated the potency of a novel antibiotic combination, PT + rifampin, to successfully eradicate ocular clinical isolates of *P. aeruginosa* with varying resistance profiles, suggesting that the combination of PT + rifampin may represent a promising new therapeutic option to fill this critical need.

**Acknowledgments**

Supported by in part by an unrestricted grant from the Research to Prevent Blindness Foundation to the Flauem Eye Institute and an NIH K08 award EY029012.

Disclosure: J.A. Mei, None; W. Johnson, None; B. Kinn, None; E. Laskey, None; L. Nolin, None; P. Bhamare, None; C. Stalker, None; P.M. Dunman, Arcum Therapeutics and Arcum Vision (I); R.A.F. Wozniak, Arcum Therapeutics and Arcum Vision (I)

**References**

1. Ung L, Bispo PJM, Shanbhag SS, Gilmore MS, Chodosh J. The persistent dilemma of microbial
keratitis: global burden, diagnosis, and antimicrobial resistance. Surv Ophthalmol. 2019;64:255–271.
2. Hilliam Y, Kaye S, Winstanley C. Pseudomonas aeruginosa and microbial keratitis. J Med Microbiol. 2020;69:3–13.
3. Ting DSJ, Ho CS, Deshmukh R, Said DG, Dua HS. Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance. Eye (Lond). 2021;35:1084–1101.
4. Subedi D, Vijay AK, Willcox M. Overview of mechanisms of antibiotic resistance in Pseudomonas aeruginosa: an ocular perspective. Clin Exp Optom. 2018;101:162–171.
5. Hoddenbach JG, Boekhoorn SS, Wubbels R, Vreugdenhil W, Van Rooij J, Geerards AJ. Clinical presentation and morbidity of contact lens-associated microbial keratitis: a retrospective study. Graefes Arch Clin Exp Ophthalmol. 2014;252:299–306.
6. Mohammadpour M, Mohajernezhadfar Z, Khodabande A, Vahedi P. Antibiotic susceptibility patterns of pseudomonas corneal ulcers in contact lens wearers. Middle East Afr J Ophthalmol. 2011;18:228–231.
7. Efroin N, Nichols JJ, Woods CA, Morgan PB. Trends in US contact lens prescribing 2002 to 2014. Optom Vis Sci. 2015;92:758–767.
8. Asbell PA, Sanfilippo CM, Pillar CM, DeCory HH, Sahm DF, Morris TW. Antibiotic resistance among ocular pathogens in the United States: five-year results from the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. JAMA Ophthalmol. 2015;133(12):1445–1554.
9. Alter SJ, Sanfilippo CM, Asbell PA, DeCory HH. Antibiotic resistance among pediatric-sourced ocular pathogens: 8-year findings from the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. Pediatr Infect Dis J. 2019;38:138–145.
10. Oldenburg CE, Lalitha P, Srinivasan M, et al. Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India. Ophthalmic Epidemiol. 2013;20:155–158.
11. Smitha S, Lalitha P, Prajna VN, Srinivasan M. Susceptibility trends of pseudomonas species from corneal ulcers. Indian J Med Microbiol. 2005;23:168–171.
12. Lalitha P, Srinivasan M, Manikandan P, et al. Relationship of in vitro susceptibility to moxifloxacin and in vivo clinical outcome in bacterial keratitis. Clin Infect Dis. 2012;54:1381–1387.
13. Kaye S, Tuft S, Neal T, et al. Bacterial susceptibility to topical antimicrobials and clinical outcome in bacterial keratitis. Invest Ophthalmol Vis Sci. 2010;51:362–368.
14. Chojnacki M, Philbrick A, Scherzi T, Pecora N, Dunman PM, Wozniak RAF. A novel, broad-spectrum antimicrobial combination for the treatment of Pseudomonas aeruginosa corneal infections. Antimicrob Agents Chemother. 2019;63(10):e00777–e00819.
15. Chojnacki M, Philbrick A, Wucher B, et al. Development of a broad-spectrum antimicrobial combination for the treatment of Staphylococcus aureus and Pseudomonas aeruginosa corneal infections. Antimicrob Agents Chemother. 2018;63(1):e01929–e02018.
16. Lichtenstein SJ, Wagner RS, Jamison T, Bell B, Stroman DW. Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies. Adv Ther. 2007;24:1098–1111.
17. Price FW, Jr, Dobbins K, Zeh W. Penetration of topically administered ofloxacin and trimethoprim into aqueous humor. J Ocul Pharmacol Ther. 2002;18:445–453.
18. Granet DB, Dorfman M, Stroman D, Cockrum P. A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J Pediatr Ophthalmol Strabismus. 2008;45:340–349.
19. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2021.
20. Kwon DH, Lu CD. Polyamines increase antibiotic susceptibility in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;50:1623–1627.
21. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52:1.
22. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.
23. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003;36:1433–1437.
resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. *Clin Infect Dis.* 2003;36:53–59.

25. Friedman ND, Temkin E, Carmeli Y. The negative impact of antibiotic resistance. *Clin Microbiol Infect.* 2016;22:416–422.

26. Centers for Disease Control and Prevention. *Antibiotic Resistance Threats in the United States, 2019.* Atlanta, GA: US Department of Health and Human Services, CDC; 2019.

27. Asbell PA, Sanfilippo CM, Sahm DF, DeCory HH. Trends in antibiotic resistance among ocular microorganisms in the United States from 2009 to 2018. *JAMA Ophthalmol.* 2020;138:439–450.

28. Poirel L, Jayol A, Nordmann P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. *Clin Microbiol Rev.* 2017;30:557–596.

29. Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. *Cell.* 2001;104:901–912.

30. Gleckman R, Blagg N, Joubert DW. Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications. *Pharmacotherapy.* 1981;1:14–20.